Genzyme seen more attractive to Sanofi than Glaxo
Of two potential suitors for biotech Genzyme , industry insiders say Sanofi-Aventis is a far more likely buyer than GlaxoSmithKline , which already has a presence in rare diseases.
Stock futures down as new home sales data eyed
Stock index futures pointed to a slightly lower open on Wall Street on Monday, as investors take a breather following last week's strong gains sparked by a flurry of reassuring company earnings.
Stock futures down; new home sales data eyed
Stock index futures pointed to a slightly lower open on Wall Street on Monday, as investors take a breather following last week's strong gains sparked by a flurry of reassuring company earnings.
Some drug firms keen, others reluctant on AIDS pool
Drugmakers Merck, Tibotec and Gilead are in advanced talks with UNITAID about a patent pool to make AIDS drugs more widely available to the poor, the health funding agency said on Wednesday.
Glaxo takes $2.4 bln charge, Avandia mostly settled
GlaxoSmithKline expects to record a legal charge of 1.57 billion pounds ($2.4 billion) for the second quarter after settling the substantial majority of claims relating to its controversial diabetes pill Avandia.
Glaxo sees $2.4 billion charge after settling Avandia claims
GlaxoSmithKline expects to record a legal charge of 1.57 billion pounds ($2.4 billion) for the second quarter after settling the substantial majority of claims relating to its controversial diabetes pill Avandia.
Glaxo expects $2.4 billion legal charge in Q2
GlaxoSmithKline expects to record a legal charge of 1.57 billion pounds ($2.4 billion) for the second quarter after settling the substantial majority of claims relating to its diabetes pill Avandia.
U.S. advisers say keep Glaxo's Avandia on the market
GlaxoSmithKline Plc's diabetes drug Avandia should be allowed to stay on the market but with additional warnings, U.S. health advisers recommended on Wednesday, easing a threat of further costly litigation that could have followed a ban.
FDA panel vote to keep diabetes drug available
U.S. health experts recommended Wednesday that GlaxoSmithKline's (GSK) diabetes drug Avandia still be sold despite the heart attack risk it poses to patient.
Instant view: U.S. advisers say keep Glaxo's Avandia on market
U.S. health advisers voted on Wednesday to keep GlaxoSmithKline's Avandia diabetes drug on the market, with a majority of those in favor recommending the treatment carry additional warnings.
Advisers say keep Glaxo's Avandia on market
U.S. health advisers said GlaxoSmithKline Plc's diabetes drug Avandia should be allowed to stay on the market in some form, easing a threat of further litigation that could have followed a ban.
Avandia wins round with FDA panel on death risk
A majority of health advisers said GlaxoSmithKline Plc's diabetes drug Avandia did not raise a concern about the risk of death when compared with other diabetes drugs.
FDA panel finds Avandia heart concern
U.S. health advisers said GlaxoSmithKline Plc's diabetes drug Avandia raised a heart attack concern compared with diabetes drugs in other classes and a rival drug in the same class.
Panel early vote finds Avandia heart concern
U.S. health advisers said GlaxoSmithKline Plc's diabetes drug Avandia raised a heart attack concern compared with diabetes drugs in other classes and a rival drug in the same class.
Panel hears final pleas on Glaxo diabetes drug
U.S. advisers neared a vote on whether a GlaxoSmithKline Plc diabetes drug carries too much heart risk to stay on the market, hearing final conflicting pleas Wednesday from a patient and a public health advocate.
U.S. panel nears vote on Glaxo diabetes drug
The fate of a GlaxoSmithKline Plc diabetes drug may become clearer on Wednesday when U.S. advisers vote on whether the widely used pill carries too much heart risk to stay on the market.
High-stakes U.S. vote nears on Glaxo diabetes drug
The fate of a GlaxoSmithKline Plc diabetes drug may become clearer on Wednesday when U.S. advisers vote on whether the widely used pill carries too much heart risk to stay on the market.
Glaxo said to settle Avandia cases on U.S. vote eve
GlaxoSmithKline Plc has agreed to pay $460 million to settle thousands of lawsuits over its Avandia diabetes pill, Bloomberg reported on Tuesday, on the eve of a crucial vote by U.S. experts on whether the pill should be withdrawn due to heart risks.
Pages
Glaxo defends Avandia to U.S. advisory panel
GlaxoSmithKline Plc insisted its diabetes pill Avandia was safe as U.S. advisers began a two-day meeting to consider if the medicine is too dangerous to stay on the market.
Experts weigh risks of Glaxo's Avandia
U.S. advisers began weighing the fate of GlaxoSmithKline Plc's diabetes pill Avandia on Tuesday at a two-day meeting that will consider if the medicine is too dangerous to stay on the market.
U.S. meeting nears on risks of Glaxo diabetes drug
A heated three-year safety debate about a GlaxoSmithKline Plc diabetes pill reaches a climax this week as opponents and backers face off at a U.S. meeting that will help decide the drug's fate.
Lawsuits may reveal more Avandia data
Lawyers for patients who say they have been harmed by GlaxoSmithKline Plc's Avandia say critical data is still under wraps even as a U.S. advisory panel prepares to weigh the fate of the controversial diabetes drug.
Diabetes drug linked to heart problem
Two recent studies linking the diabetes drug Avandia to heart ailments prompted the U.S. Food and Drug Administration (FDA) to consider withdrawing it from the market.
EU and U.S. ask if Glaxo's Avandia has a future
GlaxoSmithKline Plc's diabetes pill Avandia came under intense scrutiny on both sides of the Atlantic on Friday, leaving the drug's future uncertain as its maker battles a growing tide of lawsuits.
EU agency probes safety of Glaxo's Avandia drug
European regulators are launching a new probe into the safety of GlaxoSmithKline Plc's diabetes pill Avandia, adding to pressure on a medicine that already faces a grilling from U.S. experts next week.
- MOST READ
- 1
- 2
- 3
- 4
- 5
EDITOR'S PICK